持续气道正压通气疗程对阻塞性睡眠呼吸暂停合并2型糖尿病患者的影响:系统评价与荟萃分析
该系统评价与荟萃分析纳入14项随机对照试验共1273例阻塞性睡眠呼吸暂停合并2型糖尿病患者,评估不同疗程持续气道正压通气(CPAP)的疗效。结果显示长期CPAP干预可显著降低胰岛素抵抗指数(HOMA-IR),中远期干预可降低Epworth嗜睡量表(ESS)评分,但中远期干预与体重指数(BMI)升高相关;CPAP疗程对空腹血糖、平均血糖及糖化血红蛋白(HbA1c)无显著影响。
要点
- 长期CPAP干预可显著降低OSA合并T2DM患者的HOMA-IR水平。
- 中远期CPAP干预可显著降低ESS评分,但中远期干预与BMI升高相关。
- CPAP疗程对空腹血糖、平均血糖及HbA1c无显著影响。
核心结论
- 多項随机对照试验证据表明,CPAP治疗在OSA合并T2DM患者中的疗效随疗程而异,较长使用对胰岛素抵抗和嗜睡有益,但对关键血糖指标无显著影响。
研究设计与样本
- 系统评价与荟萃分析,纳入截至2024年12月27日发表的随机对照试验,检索MEDLINE、EMBASE和Cochrane Library,最终纳入14项研究共1273例参与者。
主要发现
- 长期CPAP干预与HOMA-IR水平显著降低相关(MD –1.67;95% CI –2.57至–0.77)。
- 中期CPAP干预后BMI升高(MD 0.31 kg/m²;95% CI 0.06至0.57),长期干预后BMI亦升高(MD 0.74 kg/m²;95% CI 0.20至1.27)。
- 中期CPAP干预后ESS评分显著降低(MD –1.45;95% CI –2.84至–0.06),长期干预后ESS亦显著降低(MD –1.79;95% CI –3.45至–0.13)。
- CPAP干预疗程对FBG、MBG或HbA1c水平的变化无显著影响。
关键数值与推荐
- CPAP干预按疗程分为短期(<12周)、中期(12–<24周)和长期(≥24周)。
临床怎么用
- 对OSA合并T2DM患者,长期CPAP治疗可能改善胰岛素抵抗和嗜睡,但需关注中远期治疗中BMI升高的风险。
- 不应期望CPAP在短期内显著改善血糖控制指标。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background Whether the efficacy of continuous positive airway pressure (CPAP) therapy differs by duration in patients with obstructive sleep apnoea (OSA) and type 2 diabetes mellitus (T2DM) is unclear. This study aimed to evaluate the effects of CPAP therapy duration on these patients. Methods We conducted a systematic review and meta-analysis of randomised controlled trials (RCTs) published up to 27 December 2024. We searched MEDLINE, EMBASE and the Cochrane Library for studies on patients with OSA and T2DM treated with CPAP. Outcomes of interest were haemoglobin A1c (HbA1c), fasting blood glucose (FBG), mean blood glucose (MBG), Homeostasis Model of Assessment of Insulin Resistance Index (HOMA-IR), body mass index (BMI) and Epworth Sleepiness Scale (ESS) score. Two reviewers independently screened studies, extracted data and assessed the risk of bias using the Cochrane risk of bias tool 2 tool. Data were synthesised using a random-effects model based on heterogeneity, and results were expressed as mean differences (MDs) with 95% CIs. Results 14 studies enrolling 1273 participants were included in the meta-analysis. The included trials were categorised into short-term (<12 weeks), medium-term (12–<24 weeks) and long-term (≥24 weeks) based on the duration of the CPAP intervention. Analysis showed that long-term CPAP intervention was associated with a significant reduction in HOMA-IR levels (MD –1.67; 95% CI –2.57 to –0.77). CPAP was associated with increases in BMI levels after medium-term (MD 0.31 kg/m 2 ; 95% CI 0.06 to 0.57) and long-term (MD 0.74 kg/m 2 ; 95% CI 0.20 to 1.27) intervention. Similarly, ESS levels showed a significant reduction after medium-term (MD –1.45; 95% CI –2.84 to –0.06) and long-term (MD –1.79; 95% CI –3.45 to –0.13) CPAP intervention. The duration of CPAP intervention did not significantly affect changes in FBG, MBG or HbA1c levels. Conclusion Evidence from multiple RCTs indicates that the efficacy of CPAP therapy varies with treatment duration in patients with OSA and T2DM, showing benefits for insulin resistance and sleepiness with longer use but no significant effect on key glycaemic markers. Trial registration number The study protocol was prospectively registered with PROSPERO ( https://www.crd.york.ac.uk/ ) (registration number: CRD42025633203).
引用
- BMJ Open Respiratory Research:Effects of continuous positive airway pressure therapy duration on patients with obstructive sleep apnoea and type 2 diabetes mellitus: a systematic review and meta-analysis
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。